Background Results of the Women's Health Initiative (WHI) study-which to many unexpectedly showed that hormone therapy (HT) did not decrease and may in fact have elevated risk of cardiovascular disease, while also finding expected links between HT and breast cancer-have spurred critical reflection chiefly regarding the cardiovascular results. Suggesting similar scrutiny of cancer epidemiology is warranted are new studies linking the post-WHI drop in HT use to a substantial decline in breast cancer incidence and the implications of these findings for prior explanations of the rising rates of US breast cancer incidence during the 1980s.
Background Results of the Women's Health Initiative (WHI) study-which to many unexpectedly showed that hormone therapy (HT) did not decrease and may in fact have elevated risk of cardiovascular disease, while also finding expected links between HT and breast cancer-have spurred critical reflection chiefly regarding the cardiovascular results. Suggesting similar scrutiny of cancer epidemiology is warranted are new studies linking the post-WHI drop in HT use to a substantial decline in breast cancer incidence and the implications of these findings for prior explanations of the rising rates of US breast cancer incidence during the 1980s.
Methods
Literature search for review and research articles on temporal trends in US breast cancer incidence during the past 25 years, starting in the mid-1980s, when extant epidemiologic evidence had already indicated that HT increased risk of breast cancer.
Results
Among the 21 articles identified, spanning from 1987 to 2007, nine included no mention of HT as a possible factor contributing to the steep rise in breast cancer incidence in the 1980s, seven included a minor mention and only five (one published in 2003, the others in 2006 and 2007) provided any substantive discussion of this issue-but only in relation to current trends and not the 1980 rise in breast cancer incidence.
Conclusion A critical appraisal of the epidemiologic literature highlights important gaps in explanations for breast cancer incidence trends and also how current and changing population patterns of disease distribution are ultimately what put our aetiologic explanations to the test.
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Routine acceptance of use of hormone therapy (HT) was shattered in 2002 by the results of the largest randomized clinical trial of HT, the 'Women's Health Initiative' (WHI). 1 Conducted in a population of mainly healthy women in the United States, this trial found that HT did not decrease, and may in fact have elevated, risk of cardiovascular disease, and it also observed expected links between HT and breast cancer. [1] [2] [3] Publication of the results triggered a dramatic and enduring drop in prescriptions and marketing of HT in the United States, with the decline in HT use exceeding 50% compared with the period prior to the WHI results ( Table 1) .
The results of the WHI have led to much critical reflection and debate. 2, 3, [14] [15] [16] [17] [18] [19] [20] [21] [22] At one level, controversies centre on the timing of HT administration for risk of coronary heart disease (CHD); [16] [17] [18] [19] [20] [21] [22] none dispute the HT-breast cancer links. At another level, the WHI results have spurred discussion about problems of confounding in observational studies, complexities involved in the design and analysis of randomized clinical trials and the enormous difficulties in testing whether potentially plausible biological pathways elucidated by basic research actually do explain disease occurrence, let alone population distributions of disease. 2, 3, [14] [15] [16] [17] [18] [19] [20] [21] [22] At issue is a core tension in scientific research: maintaining a deep humility and expansive curiosity about all that is unknown while simultaneously working to gain rigorously tested knowledge to acquire sufficient provisional certainty to guide action and interventions. 2, [23] [24] [25] [26] Focusing on the cardiovascular findings, four key lessons proposed by Petitti 14 are: 'Lesson one: do not turn a blind eye to contradiction' (i.e. allegedly different effects of estrogen in women vs men on risk of CHD); 'Lesson two: do not be seduced by mechanism' (since 'we will never know all there is to mechanism. Mechanism is complex'); 'Lesson three: suspend belief' (i.e. a belief in the protective effects of HT led to ignoring the possible role of confounding) and 'Lesson four: maintain skepticism' ('science doors that are closed have a way of reopening', in this case about hypotheses regarding the cardiovascular protective effects of HT).
Is a critical reevaluation of cancer research likewise warranted in the aftermath of the WHI? New research linking the drop in HT use to a drop in breast cancer incidence [27] [28] [29] [30] [31] [32] [33] suggests it is. Of relevance are not only the new debates about whether such a link might be causal [27] [28] [29] [30] [31] [32] [33] [34] but also-as important but thus far unconsidered-the urgent need to re-evaluate prior explanations for the notable rise of US breast cancer incidence in the 1980s. Keeping in mind Petitti's caveats, the first point to note is that a link between HT and risk of breast cancer has been well-documented in the epidemiologic literature since the mid-1970s. 2, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Postulated mechanisms involve estrogen's role as promoter (rather than initiator) of breast epithelial tissue cell growth, and especially that of tumours that are estrogen receptor positive (ER+). [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Evidence indicates that HT preferentially increases risk of breast cancer among: older women (450 years of age, partly as linked to menopausal status and duration of use), women with a lower body mass index, women with ER+ compared with ERÀ tumours, and, in the case of HT including both progestins and estrogen, lobular and ductal-lobular carcinomas. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] The WHI results prompted a new round of research on the implications of HT use for breast cancer risk, extending from beyond estimates of relative risk to the actual population burden of disease. 2, [27] [28] [29] [30] [31] [32] [33] [45] [46] [47] [48] [49] Epidemiologic analyses published between 2002 and 2005, using data from the United States, Europe and Australia, estimated that HT might account for 10-25% of observed cases. [45] [46] [47] [48] Predictions are one thing; changes in actual incidence rates are another. Notably, four new studies using post-WHI US cancer registry data have yielded findings compatible with the predicted estimates. In November 2006, Clarke et al. 27 reported that from 2001 to 2004, breast cancer incidence declined by 11% in California, including within Northern California, with use of HT among the Northern California population having declined by 68% during this same time period. Shortly thereafter, in December 2006, Ravdin et al. 28 presented a study at the San Antonio 32, 33 Building on these findings, in August 2007 a study on the population attributable impact of HT use on breast cancer incidence in the United States estimated that 'the number of breast cancers related to EP use (i.e. combined estrogen and progestin HT) could be on the order of hundreds of thousands, particularly given the elevated breast cancer risks and expanding prevalence of long-term users as time went on. For example, over the 7.5 year period between approval of Prempro and the WHI announcement (i.e. 1995 to mid-2002), over 127 000 breast cancer diagnoses could be related to EP, assuming a prevalence of EP use of 17.5% for women aged 50-79, and a relative risk of 2.0'. 49 The rapidity and magnitude of the reported breast cancer incidence decline not surprisingly invite scientific skepticism regarding a cause-effect relationship, [27] [28] [29] [30] [31] [32] [33] [34] especially given research indicating that breast tumours have an estimated doubling time of 50-100 days and require 30-35 doublings before attaining a clinically detectable size of 1 cm. 50 Alternative explanations, mentioned by Ravdin et al., 28, 29 could include declines in mammography rates, leading to reduced detection, and also potential inaccuracies in the cancer registry data. Four testable arguments countering these concerns include:
(1) The observed decline in the United States occurred uniquely for breast cancer across nine different geographic regions, implying that it was not an artefact due to errors in cancer registry reporting, as noted by Ravdin et al. 28, 29 (2) Women using or stopping use of HT, given their access to medical care, including mammography, and their greater health consciousness, [51] [52] [53] [54] [55] [56] would be more, rather than less, likely to see a physician concerning their HT use and to have a tumour detected compared with non-HT users, implying that diagnostic bias (if extant) would result in higher, not lower, breast cancer incidence rates, the opposite of what was observed. (3) With regard to mammography, Ravdin et al. 29 cited evidence of a slight decline-by 3.2%, between 2000 and 2003-in US mammography rates, arguing that it was too small to explain the observed drop in overall breast cancer incidence and also incompatible with the drop occurring only among the estrogen-receptor positive and not estrogen-receptor negative tumours. New data from the US National Health Interview Survey, moreover, not only underscore that the 2000-05 decline in mammography was modest (from 80.8 to 79.5% among women age 40 and older) 57 but also indicate that among the reasons women age 50-69 gave for not getting a mammogram in the past 2 years, the one that exhibited the greatest increase was 'too expensive/no insurance/cost' (up from 9.4 to 12.0%). Since women with lower income typically have lower risk of breast cancer compared with higher income women, 58, 59 it follows that the disproportionate presence of this group among those not getting mammograms would further minimize the impact of reduced mammography rates on breast cancer incidence. The Clarke et al. 27 study, moreover, observed a sharp drop in breast cancer incidence in Marin county, one of the wealthiest counties in the United States. (4) The biological plausibility of the hypothesis: the posited mechanism, building on extant knowledge about hormonal tumour promoters, [42] [43] [44] 46, 60, 61 is that removal of exposure to HT among tumours whose growth was especially sensitive to HT would slow or stop their growth; whether these tumours are permanently stopped or simply growing more slowly (leading to diagnosis at a later date) remains unknown. 29, 34 All of these arguments notably focus solely on the current observed drop in rates.
By implication, however, if the hypothesis that curtailing HT use could quickly lead to a marked reduction in breast cancer incidence is correct, then conceivably the reverse could be true: a substantive rise in HT use should result in higher breast cancer incidence rates. Here consideration of the recent historical record is useful. Figure 1 shows well-known trends in the agespecific incidence of invasive breast cancer among US white women from 1937 to 1939 to 2003, drawing on data from the First, Second and Third National Cancer Surveys and the more recent SEER data. [62] [63] [64] [65] [66] [67] Results are shown only for the white women because they are the group most likely to exhibit HT-related changes in breast cancer incidence, given extensive documentation that HT use in the United States, at least until 2002, was most common among more affluent, healthier and predominantly white women, i.e. women with access to medical care, who could afford HT, and who did not have contraindications against its use.
2,51-56,68-72 The importance of presenting data solely on this group, rather than the total population, is indicated by Table 2 , which shows the marked increase, between 1980 and 2005, and especially most recently, in the proportion of the SEER and US populations that were foreign-born (from 7.2 to 13.8% and from 6.2 to 12.4%, respectively) and of colour (from 19.9 to 30.1% and from 16.6 to 25.3%, respectively). Since breast cancer incidence rates are typically lower among both the US foreign-born population and populations of colour, compared with US-born white women, 58, 59 presenting data on the total population would potentially confound HT-related temporal trends in breast cancer incidence with demographic trends.
As Figure 1 shows, the age-specific incidence rates began rising especially quickly among women age 50 and older starting in the early 1980s. A new study has quantified the trends in the SEER data for and reported that the largest increase among white women occurred between 1982 and 1987 among women aged 50 and older who had localized tumours, with the annual percent change equaling 9.9% (a magnitude significantly different from 0); in contrast, among this same group, the annual percent change for 1975-82 was only 0.9% (not significantly different from 0), for 1987-99 it was only 1.7% (significantly different from 0) and for 1999-2002 it was À1.9% (not significantly different from 0). 73 This 9.9% annual percent change in the 1980s is noteworthy for two reasons. First, this annual percent increase is of the same order of magnitude as the currently observed drop in breast cancer incidence rates among women over age 50. Second, it occurred at a time when not only mammography rates were rising, as has been previously noted, [74] [75] [76] but also when HT use was dramatically increasing, especially the combined estrogen-progestin formulations, following a period in the mid-1970s when use of HT dropped due to the growing evidence linking estrogen-only HT and endometrial cancer. 2, 9, 19, 77, 78 Keeping these data in mind, it is useful to review how numerous epidemiologic studies and review articles have explained the marked rise in US breast cancer incidence rates that occurred chiefly among women age 50 and older starting in the early 1980s. Table 3 presents a summary of articles published since the mid-1980s that have focused on temporal trends in US breast cancer incidence over the last 25 years, 30, 31, [73] [74] [75] [76] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] noting that by the start of this period epidemiologic evidence had already indicated that HT increased risk of breast cancer. and more than a decade after the epidemiologic evidence on these links were considered to be sufficiently robust to be a cause for serious concern, outweighing any then-presumed cardiovascular benefits, 38 did articles on US breast cancer trends begin to focus on HT use as a potentially important driver of population rates of breast cancer. 30, 31, 73, 88, 92 In other words, the lessons Petitti has drawn based on the cardiovascular-HT research apply equally to breast cancer. The point is not that the mammography explanation for the rapid rise in breast cancer incidence rates in the 1980s was 'wrong': part of the rise was shown to be due to increased rates of mammography and increased detection. [73] [74] [75] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] Nor is the point that use of HT is more important than the other known risk factors for breast cancer. Rather, the problem is that since the mid-1980s, when extant knowledge linked HT use to risk of breast cancer, epidemiologic articles on trends in breast cancer incidence tended to offer scant or no mention of HT as a meaningful contributor to breast cancer incidence rates. Moreover, it was not until after the actual incidence of breast cancer fell, post-WHI, that connections between current drops in population rates of HT use and current declines in breast cancer incidence rates began to receive widespread attention, among epidemiologists, clinicians and the public at large 34 -albeit without any parallel re-analysis of the 1980s rise in HT use and rise in breast cancer incidence.
At one level, the changing views in the breast cancer literature are not surprising: scientific research abounds with examples of old observations re-interpreted in the light of new hypotheses and new evidence [23] [24] [25] [26] (consider only the rethinking of ulcers and gastric cancer in relation to infection by Helicobacter Pylori 25 (pp.39-97) 94, 95 ). More disturbing is the possibility that scientific hypotheses were influenced by deeply held beliefs in the benefits of science. 2, 23 Specifically, the expectation of greater detection hence higher incidence due to the intervention of mammography was more in keeping with the beliefs and values of cancer control (even taking into account concerns about false positives) than the alternative of iatrogenic harm. The implication is that it is essential to maintain a critical awareness of how interventions framed as 'medical advances' can damage, not just improve, population health, especially when economic interests are at play, 2 as recent concerns about the overhyping of benefits and minimization or suppression of risks of several major pharmaceutical products readily reveals. Increasing mammography rates and birth cohort changes in risk factors ('age at menarche, age at first birth, physical activity, obesity, diet, alcohol intake, estrogen therapy, and exposure to organochlorines'), noting that insufficient data existed to evaluate the HT hypothesis (p. 453) Using age-period-cohort framework, conclude that 'the overall increase in breast cancer incidence is almost certainly due to multiple factors, including screening as well as etiological risk factors', accounting for divergence in trends for birth cohorts born before and after 1925 for women older and younger than age 50, noting that 'Among the breast cancer risk factor exposures that changed for these more recent birth cohorts are fewer children, increased age at first pregnancy, obesity, and increased use of hormone replacement therapy, all of which are qualitatively consistent with the postmenopausal increase in risk with birth cohort that is apparent from these analyses' (p. 24) 
HT AND BREAST CANCER RATES Another key lesson concerns the value of population data, including cancer registry data. 97 Especially in this era of genomic research and increasingly molecularized epidemiology, the new data on breast cancer incidence trends underscore how current and changing population patterns of disease distribution are ultimately what put our aetiologic explanations to the test. 26, [98] [99] [100] [101] [102] Whether or not current knowledge and hypotheses about the biological mechanisms of breast cancer aetiology would predict a rapid and substantial drop in breast cancer incidence following marked reductions in HT use, we are confronted by the observed recent sharp decline. This drop calls for explanation. Between the Scylla of too much scientific skepticism and the Charybdis of too much scientific certainty-whether about observed population data, postulated mechanisms or methods-it will be necessary to navigate a course of research and action moored to actual trends in breast cancer incidence and cognizant of, but not stranded by, the inevitable limitations of scientific knowledge. 
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KEY MESSAGES
Results of the WHI study have spurred critical reflection, chiefly regarding the cardiovascular results.
Suggesting similar scrutiny of cancer epidemiology is warranted are new studies linking the post-WHI drop in HT use to a substantial decline in breast cancer incidence and the implications of these findings for prior explanations of rising rates of US breast cancer incidence during the 1980s.
A review of 21 epidemiologic review and research articles on temporal trends in US breast cancer incidence, spanning from 1987 to 2007, found that nine included no mention of HT as a possible factor of the steeply rise in rates of breast cancer incidence in the 1980s, seven included a minor mention and only five (one published in 2003, the others in 2006 and 2007) provided any substantive discussion of this issue-but only in relation to current trends and not the 1980 rise in breast cancer incidence.
These results reveal not only important gaps in explanations for breast cancer incidence trends but also highlight how current and changing population patterns of disease distribution are ultimately what put our aetiologic explanations to the test.
